Mitigation of Radiation Pneumonitis and Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 1, 2013

Primary Completion Date

April 1, 2018

Study Completion Date

April 1, 2018

Conditions
Lung CancerRadiation Pneumonitis
Interventions
DRUG

Enalapril

Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer

DRUG

placebo

Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer

Trial Locations (3)

21201

Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore

48105

VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor

53295-1000

Clement J. Zablocki VA Medical Center, Milwaukee, WI, Milwaukee

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT01754909 - Mitigation of Radiation Pneumonitis and Fibrosis | Biotech Hunter | Biotech Hunter